sulfinpyrazone has been researched along with Respiratory Distress Syndrome, Newborn in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Respiratory Distress Syndrome, Newborn: A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verstraete, M | 1 |
1 trial available for sulfinpyrazone and Respiratory Distress Syndrome, Newborn
| Article | Year |
|---|---|
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |